Related Experiment Videos
Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation
1Departments of Biochemistry and Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, USA.
The Journal of Biological Chemistry
|June 22, 2000
Summary
The antibiotic geldanamycin triggers the breakdown of ErbB-2 (a co-receptor tyrosine kinase) in cancer cells. Its kinase domain is crucial for this degradation, which involves distinct pathways for different fragments.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- ErbB-2 is a co-receptor tyrosine kinase frequently overexpressed in various human tumors.
- Geldanamycin, an antibiotic, has been observed to induce ErbB-2 degradation in carcinoma cell lines.
Purpose of the Study:
- To investigate the role of the ErbB-2 kinase domain in geldanamycin-induced degradation.
- To elucidate the mechanistic pathways involved in ErbB-2 degradation by geldanamycin.
Main Methods:
- Utilized ErbB-2 mutants, chimeric receptors, and green fluorescent protein fusion proteins.
- Assessed the sensitivity of epidermal growth factor receptor kinase domain to geldanamycin.
- Employed proteasome inhibitors and endocytosis pathway inhibitors.
- Conducted confocal microscopy studies.
Main Results:
- The kinase domain of ErbB-2 is essential for geldanamycin-induced degradation.
- The kinase domain of epidermal growth factor receptor is not sensitive to geldanamycin.
- Geldanamycin induces cleavage of ErbB-2 into 135-kDa and 23-kDa fragments.
- Degradation of the 23-kDa fragment is proteasome-dependent; degradation of the 135-kDa fragment is endocytosis-dependent.
- Geldanamycin induces intracellular vesicular localization of ErbB-2.
Conclusions:
- Geldanamycin-induced ErbB-2 degradation is dependent on its kinase domain.
- The degradation process involves distinct pathways for different ErbB-2 fragments, highlighting complex cellular mechanisms.
- Findings provide insights into targeting ErbB-2 in cancer therapy.